Profusa Stock Set to Reverse Split on Monday, August 17th (NASDAQ:PFSA)

Profusa, Inc. (NASDAQ:PFSAFree Report) shares are set to reverse split on Monday, August 17th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 16th.

Profusa Stock Down 1.5%

PFSA traded down $0.01 during trading on Thursday, reaching $0.95. The company had a trading volume of 197,899 shares, compared to its average volume of 624,052. The business has a 50 day simple moving average of $2.85 and a 200-day simple moving average of $25.06. Profusa has a 52 week low of $0.81 and a 52 week high of $1,297.50.

Analyst Ratings Changes

Several brokerages have recently weighed in on PFSA. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

View Our Latest Research Report on PFSA

About Profusa

(Get Free Report)

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.

Further Reading

Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.